相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
Anilkumar Gopalakrishnapillai et al.
CANCERS (2021)
Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia
Noortje van Gils et al.
FRONTIERS IN ONCOLOGY (2021)
Targeting Telomere Biology in Acute Lymphoblastic Leukemia
Axel Karow et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis
John Mascarenhas et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia
Gabriela M. Baerlocher et al.
BLOOD ADVANCES (2019)
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
Hamid Bolouri et al.
NATURE MEDICINE (2018)
Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells
Xiaoli Wang et al.
BLOOD ADVANCES (2018)
Leukemic stem cells: identification and clinical application
Diana Hanekamp et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis
G. Mosoyan et al.
LEUKEMIA (2017)
Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia
Anilkumar Gopalakrishnapillai et al.
LEUKEMIA RESEARCH (2017)
Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS
Xin Zhao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines
Joshua Rusbuldt et al.
CANCER RESEARCH (2016)
Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice
Anilkumar Gopalakrishnapillai et al.
FRONTIERS IN ONCOLOGY (2016)
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
Gabriela M. Baerlocher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression
Xiaolu Zhang et al.
ONCOTARGET (2015)
Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy
Claudia Bruedigam et al.
CELL STEM CELL (2014)
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
C. Craddock et al.
LEUKEMIA (2013)
Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia
A. M. Aalbers et al.
LEUKEMIA (2013)
Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia
Andrew J. Gentles et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia
Rodrigo T. Calado et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition
BS Herbert et al.
ONCOGENE (2005)
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia - Comparison with adult acute myeldid leukemia
S Verstovsek et al.
CANCER (2003)
分享论文
